ZYVERSA THERAPEUTICS, INC. Adjustments to Additional Paid in Capital, Other
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Adjustments to Additional Paid in Capital, Other of $53.89 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2026-05-13
- ZYVERSA THERAPEUTICS, INC. adjustments to additional paid in capital, other for the quarter ending 2026-03-31 was $53.89K, a 0.00% change year-over-year.
- ZYVERSA THERAPEUTICS, INC. adjustments to additional paid in capital, other for the quarter ending 2025-12-31 was -$1.76M.
- ZYVERSA THERAPEUTICS, INC. adjustments to additional paid in capital, other for the quarter ending 2025-09-30 was $1.76M, a 613.92% increase year-over-year.
- ZYVERSA THERAPEUTICS, INC. adjustments to additional paid in capital, other for the quarter ending 2025-06-30 was $0.00.
- ZYVERSA THERAPEUTICS, INC. adjustments to additional paid in capital, other for fiscal 2025 was $53.89K.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 6 month | Adjustments to Additional Paid in Capital, Other 9 month | Adjustments to Additional Paid in Capital, Other 12 month |
|---|---|---|---|---|
| 2026-03-31 | $53.89K 10-Q · filed 2026-05-13 | -$1.71M derived: sum of 2 quarters · filed 2026-05-13 | $53.89K derived: sum of 3 quarters · filed 2026-05-13 | $53.89K derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | -$1.76M derived: 10-K 12 month − 3 quarters · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-03-31 | $53.89K 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.76M 10-Q · filed 2025-11-19 | $1.76M derived: sum of 2 quarters · filed 2025-11-19 | $1.82M derived: sum of 3 quarters · filed 2025-11-19 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $53.89K 10-Q · filed 2025-08-13 | ||
| 2025-03-31 | $53.89K 10-Q · filed 2025-11-19 | |||
| 2024-09-30 | $246.91K 10-Q · filed 2025-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |